Selumetinib

Chemical formula: C₁₇H₁₅BrClFN₄O₃  Molecular mass: 457.68 g/mol  PubChem compound: 10127622

Therapeutic indications

Selumetinib is indicated for:

Neurofibromatosis type 1 (NF1) with plexiform neurofibromas (PN)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Selumetinib as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Selumetinib is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Severe hepatic impairment

Hepatic failure stage IV

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2020: KOSELUGO Capsule
Summary of Product Characteristics (SPC) 2021: KOSELUGO Hard capsule
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈